News

Neurimmune joins ACCESS-AD consortium, an innovative health initiative to accelerate timely and equitable AD diagnosis, treatment and care

News 14.01.2026 Zurich, Switzerland - 13.01.2026 Neurimmune today announced that the company joined the ACCESS-AD consortium, a new European initiative to accelerate the implementation of scientific innovations for Alzheimer’s disease (AD) management in real-world health systems. The international consortium - bringing together academic institutions, industry partners, SMEs and patient organisations - is a five-year...

read more

Kuros Biosciences to provide investor update at Octavian and Baader Bank Conferences

News 13.01.2026 Schlieren (Zürich), Switzerland, January 13, 2026 – Kuros Biosciences (“Kuros” or the “Company”) a leader in innovative biologic technologies, today announced a series of milestones including key IDN (Integrated Delivery Network) health system approvals, significant regulatory approval, and published preclinical evidence supporting the continued adoption and global expansion of MagnetOs™,...

read more

Memo Therapeutics AG Publishes BKPyV Infection Disease Burden Study in the Journal of Patient-Reported Outcomes

News 12.01.2026 Schlieren / Zurich, Switzerland, 9 January, 2026 – Memo Therapeutics AG (“MTx”), a late-stage biotech company translating unique human immune responses into superior medicines to treat viral infections and cancer, today announces the publication of a qualitative research paper titled ‘Development of a Conceptual Model of BKV Impacts on Health-Related Quality of Life...

read more

Molecular Partners Highlights Clinical Development Progress and Anticipated Milestones at 44th Annual J.P. Morgan Healthcare Conference

News 12.01.2026 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Jan. 11, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today provided an update...

read more

Virometix AG Announces Positive Data from Phase 1 Trial of V-212, a Fully Synthetic, Serotype-Independent Vaccine Development Candidate for the Prevention of Pneumococcal Disease

News 09.01.2026 SCHLIEREN, Switzerland--(BUSINESS WIRE)--Virometix AG, a clinical-stage biotechnology company pioneering fully synthetic vaccines, today announced positive topline data from the Company’s Phase 1 trial of its lead asset V-212, a serotype-independent pneumococcal vaccine candidate, in development for the prevention of pneumococcal disease caused by Streptococcus pneumoniae (Spn) infections. The study evaluated safety and...

read more